Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
GRI BIO, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "A New Approach to Inflammatory Diseases NASDAQ: GRI"
08/23/2023 8-K Acquisition/merger/asset purchase announced
Docs: "GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU"
08/14/2023 8-K Quarterly results
Docs: "GRI Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases"
07/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/27/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET Over 90% of the shares voted to date have shown support “FOR” each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio"
03/31/2023 8-K Other Events  Interactive Data
03/02/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
02/24/2023 8-K Quarterly results
Docs: "Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results"
01/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
12/29/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/13/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "AGREEMENT AND PLAN OF MERGER",
"WARRANT",
"[FORM OF SERIES [A-1] [A-2] [T] WARRANT&#93",
"[FORM OF EXCHANGE WARRANT] GRI BIO, INC.",
"REGISTRATION RIGHTS AGREEMENT",
"SUPPORT AGREEMENT",
"SUPPORT AGREEMENT",
"LOCK-UP AGREEMENT",
"SECURITIES PURCHASE AGREEMENT",
"SECURITIES PURCHASE AGREEMENT"
11/03/2022 8-K Quarterly results
07/28/2022 8-K Quarterly results
Docs: "Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update"
07/26/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT",
"AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT"
07/13/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/28/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/18/2022 8-K Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Even...
Docs: "AMENDMENT NO. 1 TO THE"
05/13/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
Docs: "Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update"
04/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vallon Pharmaceuticals Announces Review of Strategic Alternatives"
03/30/2022 8-K Resignation/termination of a director
03/21/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
02/14/2022 8-K Quarterly results
Docs: "Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update - Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter"
12/23/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022"
10/12/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy